布地奈德作用效果

First developed and marketed by AstraZeneca Pharmaceuticals in 1981, it is a non-halogenated glucocorticoid that has a strong local anti-inflammatory effect and can inhibit early bronchospasm and late allergic reactions. It is one of the important drugs for the treatment of allergic asthma. Budesonide has a strong local anti-inflammatory effect, and its mechanism may be: enhancing the stability of mast cells and lysosomal membranes, reducing degranulation and the release of lysosomal enzymes; anti-immune effects, inhibiting inflammation caused by immune responses, etc.; for patients with airway hyperresponsiveness, this product can significantly reduce the airway response to histamine and methacholine.

The nebulized dosage of budesonide is generally 1-2 mg once for adults, twice a day; for children, 0.5-1 mg once, twice a day. The maintenance dose should be individualized, that is, the lowest dose to maintain no symptoms. It is recommended that adults take 0.5-1 mg twice a day and children 0.25-0.5 mg twice a day. Patients should take budesonide about half an hour before meals and swallow the budesonide whole with plenty of liquid (such as a glass of water). Swallow whole. Do not chew or crush. Avoid grapefruit juice during treatment.

The clinical trial selected 85 patients with bronchial asthma who received treatment and divided them into an experimental group of 43 patients and a control group of 42 patients using the random number table method. Patients in the control group were treated with albuterol sulfate, and patients in the experimental group were treated with budesonide. After 2 weeks, the treatment effects and incidence of adverse reactions were compared. Results: The treatment effectiveness rate of patients in the experimental group was 95.35%, which was significantly higher than the 69.05% in the control group, and the difference was statistically significant. No patients in the two groups experienced serious adverse reactions. The incidence of adverse reactions in the experimental group was significantly lower than that in the control group, and the difference was statistically significant.

Conclusion: It has significant efficacy and high safety when applied to bronchial asthma. Currently, budesonide is not on the market in the country. For detailed information, please consult the medical companion travel service.